Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas

Susan B. Kesmodel, Giorgos C. Karakousis, Jeffrey D. Botbyl, Robert J Canter, Robert T. Lewis, Peter M. Wahl, Kyla P. Terhune, Abass Alavi, David E. Elder, Michael E. Ming, Dupont Guerry, Phyllis A. Gimotty, Douglas L. Fraker, Brian J. Czerniecki, Francis R. Spitz

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Lymphatic mapping and sentinel lymphadenectomy (LM/SL) provide important prognostic information for patients with early-stage melanoma. Although the use of this technique in patients with thin melanomas (1.00 mm) is not routine, risk factors that may predict sentinel lymph node (SLN) positivity in this patient population are under investigation. We sought to determine whether mitotic rate (MR) is associated with SLN positivity in thin-melanoma patients and, therefore, whether it may be used to risk-stratify and select patients for LM/SL. Clinical and histopathologic variables were reviewed for 181 patients with thin melanomas who underwent LM/SL from January 1996 through January 2004. Univariate and multivariate logistic regression analyses were performed to identify factors associated with SLN positivity. Risk groups were defined on the basis of the development of a classification tree. The overall SLN positivity rate was 5%. All patients with positive SLNs had an MR of >0. By univariate analysis, MR and thickness were significant predictors of SLN positivity. The association between MR and SLN positivity remained significant controlling for each of the other variables evaluated. On the basis of a classification tree, patients with an MR >0 and tumor thickness .76 mm were identified as a higher-risk group, with an SLN positivity rate of 12.3%. In patients with thin melanomas, MR >0 seems to be a significant predictor of SLN positivity that may be used to risk-stratify and select patients for LM/SL. To confirm these results, the predictive value of MR for SLN positivity needs to be validated in other populations of thin-melanoma patients.

Original languageEnglish (US)
Pages (from-to)449-458
Number of pages10
JournalAnnals of Surgical Oncology
Volume12
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Lymph
Melanoma
Lymph Node Excision
cyhalothrin
Sentinel Lymph Node
Population
Logistic Models
Regression Analysis

Keywords

  • Mitotic rate
  • Sentinel lymphadenectomy
  • SLN positivity
  • Thin melanomas
  • Tumor-thickness

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Kesmodel, S. B., Karakousis, G. C., Botbyl, J. D., Canter, R. J., Lewis, R. T., Wahl, P. M., ... Spitz, F. R. (2005). Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas. Annals of Surgical Oncology, 12(6), 449-458. https://doi.org/10.1245/ASO.2005.04.027

Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas. / Kesmodel, Susan B.; Karakousis, Giorgos C.; Botbyl, Jeffrey D.; Canter, Robert J; Lewis, Robert T.; Wahl, Peter M.; Terhune, Kyla P.; Alavi, Abass; Elder, David E.; Ming, Michael E.; Guerry, Dupont; Gimotty, Phyllis A.; Fraker, Douglas L.; Czerniecki, Brian J.; Spitz, Francis R.

In: Annals of Surgical Oncology, Vol. 12, No. 6, 06.2005, p. 449-458.

Research output: Contribution to journalArticle

Kesmodel, SB, Karakousis, GC, Botbyl, JD, Canter, RJ, Lewis, RT, Wahl, PM, Terhune, KP, Alavi, A, Elder, DE, Ming, ME, Guerry, D, Gimotty, PA, Fraker, DL, Czerniecki, BJ & Spitz, FR 2005, 'Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas', Annals of Surgical Oncology, vol. 12, no. 6, pp. 449-458. https://doi.org/10.1245/ASO.2005.04.027
Kesmodel, Susan B. ; Karakousis, Giorgos C. ; Botbyl, Jeffrey D. ; Canter, Robert J ; Lewis, Robert T. ; Wahl, Peter M. ; Terhune, Kyla P. ; Alavi, Abass ; Elder, David E. ; Ming, Michael E. ; Guerry, Dupont ; Gimotty, Phyllis A. ; Fraker, Douglas L. ; Czerniecki, Brian J. ; Spitz, Francis R. / Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas. In: Annals of Surgical Oncology. 2005 ; Vol. 12, No. 6. pp. 449-458.
@article{a043a48e01c34edf8d83f252177714f5,
title = "Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas",
abstract = "Lymphatic mapping and sentinel lymphadenectomy (LM/SL) provide important prognostic information for patients with early-stage melanoma. Although the use of this technique in patients with thin melanomas (1.00 mm) is not routine, risk factors that may predict sentinel lymph node (SLN) positivity in this patient population are under investigation. We sought to determine whether mitotic rate (MR) is associated with SLN positivity in thin-melanoma patients and, therefore, whether it may be used to risk-stratify and select patients for LM/SL. Clinical and histopathologic variables were reviewed for 181 patients with thin melanomas who underwent LM/SL from January 1996 through January 2004. Univariate and multivariate logistic regression analyses were performed to identify factors associated with SLN positivity. Risk groups were defined on the basis of the development of a classification tree. The overall SLN positivity rate was 5{\%}. All patients with positive SLNs had an MR of >0. By univariate analysis, MR and thickness were significant predictors of SLN positivity. The association between MR and SLN positivity remained significant controlling for each of the other variables evaluated. On the basis of a classification tree, patients with an MR >0 and tumor thickness .76 mm were identified as a higher-risk group, with an SLN positivity rate of 12.3{\%}. In patients with thin melanomas, MR >0 seems to be a significant predictor of SLN positivity that may be used to risk-stratify and select patients for LM/SL. To confirm these results, the predictive value of MR for SLN positivity needs to be validated in other populations of thin-melanoma patients.",
keywords = "Mitotic rate, Sentinel lymphadenectomy, SLN positivity, Thin melanomas, Tumor-thickness",
author = "Kesmodel, {Susan B.} and Karakousis, {Giorgos C.} and Botbyl, {Jeffrey D.} and Canter, {Robert J} and Lewis, {Robert T.} and Wahl, {Peter M.} and Terhune, {Kyla P.} and Abass Alavi and Elder, {David E.} and Ming, {Michael E.} and Dupont Guerry and Gimotty, {Phyllis A.} and Fraker, {Douglas L.} and Czerniecki, {Brian J.} and Spitz, {Francis R.}",
year = "2005",
month = "6",
doi = "10.1245/ASO.2005.04.027",
language = "English (US)",
volume = "12",
pages = "449--458",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas

AU - Kesmodel, Susan B.

AU - Karakousis, Giorgos C.

AU - Botbyl, Jeffrey D.

AU - Canter, Robert J

AU - Lewis, Robert T.

AU - Wahl, Peter M.

AU - Terhune, Kyla P.

AU - Alavi, Abass

AU - Elder, David E.

AU - Ming, Michael E.

AU - Guerry, Dupont

AU - Gimotty, Phyllis A.

AU - Fraker, Douglas L.

AU - Czerniecki, Brian J.

AU - Spitz, Francis R.

PY - 2005/6

Y1 - 2005/6

N2 - Lymphatic mapping and sentinel lymphadenectomy (LM/SL) provide important prognostic information for patients with early-stage melanoma. Although the use of this technique in patients with thin melanomas (1.00 mm) is not routine, risk factors that may predict sentinel lymph node (SLN) positivity in this patient population are under investigation. We sought to determine whether mitotic rate (MR) is associated with SLN positivity in thin-melanoma patients and, therefore, whether it may be used to risk-stratify and select patients for LM/SL. Clinical and histopathologic variables were reviewed for 181 patients with thin melanomas who underwent LM/SL from January 1996 through January 2004. Univariate and multivariate logistic regression analyses were performed to identify factors associated with SLN positivity. Risk groups were defined on the basis of the development of a classification tree. The overall SLN positivity rate was 5%. All patients with positive SLNs had an MR of >0. By univariate analysis, MR and thickness were significant predictors of SLN positivity. The association between MR and SLN positivity remained significant controlling for each of the other variables evaluated. On the basis of a classification tree, patients with an MR >0 and tumor thickness .76 mm were identified as a higher-risk group, with an SLN positivity rate of 12.3%. In patients with thin melanomas, MR >0 seems to be a significant predictor of SLN positivity that may be used to risk-stratify and select patients for LM/SL. To confirm these results, the predictive value of MR for SLN positivity needs to be validated in other populations of thin-melanoma patients.

AB - Lymphatic mapping and sentinel lymphadenectomy (LM/SL) provide important prognostic information for patients with early-stage melanoma. Although the use of this technique in patients with thin melanomas (1.00 mm) is not routine, risk factors that may predict sentinel lymph node (SLN) positivity in this patient population are under investigation. We sought to determine whether mitotic rate (MR) is associated with SLN positivity in thin-melanoma patients and, therefore, whether it may be used to risk-stratify and select patients for LM/SL. Clinical and histopathologic variables were reviewed for 181 patients with thin melanomas who underwent LM/SL from January 1996 through January 2004. Univariate and multivariate logistic regression analyses were performed to identify factors associated with SLN positivity. Risk groups were defined on the basis of the development of a classification tree. The overall SLN positivity rate was 5%. All patients with positive SLNs had an MR of >0. By univariate analysis, MR and thickness were significant predictors of SLN positivity. The association between MR and SLN positivity remained significant controlling for each of the other variables evaluated. On the basis of a classification tree, patients with an MR >0 and tumor thickness .76 mm were identified as a higher-risk group, with an SLN positivity rate of 12.3%. In patients with thin melanomas, MR >0 seems to be a significant predictor of SLN positivity that may be used to risk-stratify and select patients for LM/SL. To confirm these results, the predictive value of MR for SLN positivity needs to be validated in other populations of thin-melanoma patients.

KW - Mitotic rate

KW - Sentinel lymphadenectomy

KW - SLN positivity

KW - Thin melanomas

KW - Tumor-thickness

UR - http://www.scopus.com/inward/record.url?scp=21244433509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244433509&partnerID=8YFLogxK

U2 - 10.1245/ASO.2005.04.027

DO - 10.1245/ASO.2005.04.027

M3 - Article

C2 - 15864482

AN - SCOPUS:21244433509

VL - 12

SP - 449

EP - 458

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -